Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres

Respirology

Volumn 21, Issue 2, 2016, Pages 329-337

  Smith, Daniel J ^a,b,c   Ramsay, Kay A ^c,d   Yerkovich, Stephanie T ^a,b   Reid, David W ^a,b,c   Wainwright, Claire E ^d   Grimwood, Keith ^d,e   Bell, Scott C ^a,b,c,d   Kidd, Timothy J ^c,f  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

antibiotic resistance; cystic fibrosis; epidemiology; Pseudomonas aeruginosa; treatment

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DORNASE ALFA; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIAN; BACTERIAL STRAIN; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; LABORATORY TEST; LUNG FUNCTION; MALE; MORBIDITY; MORTALITY; PEDIATRICS; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REGISTER; AUSTRALIA; CHILD; CLINICAL PRACTICE; COMPLICATION; DRUG EFFECTS; DRUG UTILIZATION; HEALTH CARE FACILITY; INTRAVENOUS DRUG ADMINISTRATION; LUNG FUNCTION TEST; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTIONS; SEX DIFFERENCE; SPUTUM;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTI-BACTERIAL AGENTS; AUSTRALIA; AZITHROMYCIN; BODY MASS INDEX; CHILD; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; FEMALE; HEALTH FACILITIES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PRACTICE PATTERNS, PHYSICIANS'; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REGISTRIES; RESPIRATORY FUNCTION TESTS; SEX FACTORS; SPUTUM;

EID: 84955276376     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12714     Document Type: Article

References (39)

1. Cohen-Cymberknoh M, Shoseyov D, Kerem E,. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am. J. Respir. Crit. Care Med. 2011; 183: 1463-1471.
2. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H, et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur. Respir. J. 2014; 43: 125-133.
3. Doring G, Flume P, Heijerman H, Elborn JS, Consensus Study G. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012; 11: 461-479.
4. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies C. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 2009; 180: 802-808.
5. Fothergill JL, Walshaw MJ, Winstanley C,. Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur. Respir. J. 2012; 40: 227-238.
6. Corey M, McLaughlin FJ, Williams M, Levison H,. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J. Clin. Epidemiol. 1988; 41: 583-591.
7. Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D, Marinelli I, Messore B, Neri AS, Raia V, et al. An overview of international literature from cystic fibrosis registries. Part 4: update 2011. J. Cyst. Fibros. 2012; 11: 480-493.
8. Boyle MP, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS,. Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project. BMJ Qual. Saf. 2014; 23 (Suppl. 1): i15-22.
9. Kidd TJ, Ramsay KA, Hu H, Marks GB, Wainwright CE, Bye PT, Elkins MR, Robinson PJ, Rose BR, Wilson JW, et al. Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres. Eur. Respir. J. 2013; 41: 1091-1100.
10. Cystic Fibrosis Australia. Cystic Fibrosis in Australia 2009: 12th Annual Report from the Australian Cystic Fibrosis Data Registry. Sydney: Cystic Fibrosis Australia 2011, 2011.
11. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr,. Pulmonary function between 6 and 18 years of age. Pediatr. Pulmonol. 1993; 15: 75-88.
12. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am. J. Respir. Crit. Care Med. 1999; 159: 179-187.
13. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL,. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat. 11 2002; 246: 1-190.
14. Wolter JM, Kotsiou G, McCormack JG,. Mixed morphotype testing of Pseudomonas aeruginosa cultures from cystic fibrosis patients. J. Med. Microbiol. 1995; 42: 220-224.
15. Bell SM, Pham JN, Fisher GT,. Antibiotic susceptibility testing by the CDS method: a manual for medical and veterinary laboratories 2009. 5th edn. Sydney: The Antibiotic Reference Laboratory. South Eastern Area Laboratory Services; 2009.
16. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and Zone Diameters, Version 1.3: European Committee on Antimicrobial Susceptibility Testing; 2011. [Accessed 14 Nov 2014.] Available from URL: http://www.eucast.org/clinical-breakpoints
17. Clinical and Laboratory Standards Institute. Performance standards for testing: twenty-first informational supplement M100-S21. Antimicrobial Susceptibility Testing. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2011.
18. Kidd TJ, Ramsay KA, Hu H, Bye PT, Elkins MR, Grimwood K, Harbour C, Marks GB, Nissen MD, Robinson PJ, et al. Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J. Clin. Microbiol. 2009; 47: 1503-1509.
19. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A,. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 1996; 23: 532-537.
20. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N,. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007; 132: 562-568.
21. Strateva T, Yordanov D,. Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J. Med. Microbiol. 2009; 58 (Pt 9): 1133-1148.
22. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y,. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin. Infect. Dis. 1999; 28: 1128-1133.
23. Su S, Hassett DJ,. Anaerobic Pseudomonas aeruginosa and other obligately anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"? Expert Opin. Ther. Targets 2012; 16: 859-873.
24. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002; 109: 317-325.
25. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y,. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 2006; 50: 43-48.
26. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH,. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 1999; 43: 1379-1382.
27. Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR,. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J. Cyst. Fibros. 2012; 11: 288-292.
28. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL,. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 1495-1502.
29. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP,. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006; 73: 27-33.
30. Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, Regelmann W, Scientific Advisory Group I, Coordinators of the Epidemiologic Study of Cystic F. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J. Cyst. Fibros. 2012; 11: 293-299.
31. Davies G, McShane D, Davies JC, Bush A,. Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation. Pediatr. Pulmonol. 2003; 35: 253-256.
32. Parmar JS, Nasser S,. Antibiotic allergy in cystic fibrosis. Thorax 2005; 60: 517-520.
33. Prayle A, Smyth AR,. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr. Opin. Pulm. Med. 2010; 16: 604-610.
34. Sawicki GS, Sellers DE, Robinson WM,. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J. Cyst. Fibros. 2009; 8: 91-96.
35. Cramer N, Wiehlmann L, Ciofu O, Tamm S, Hoiby N, Tummler B,. Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis. PLoS ONE 2012; 7: e50731.
36. Dalhoff A,. Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients. Clin. Microbiol. Rev. 2014; 27: 753-782.
37. Miller MB, Gilligan PH,. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J. Clin. Microbiol. 2003; 41: 4009-4015.
38. Radhakrishnan DK, Corey M, Dell SD,. Realities of expectorated sputum collection in the pediatric cystic fibrosis clinic. Arch. Pediatr. Adolesc. Med. 2007; 161: 603-606.
39. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011; 306: 163-171.